Emdogain – Available in the USA again

The FDA has reinspected the BIORA facility and is satisfied with the improvements made. Because the focus of the observations was on the maintenance of quality system documentation and procedures, changes to Straumann® Emdogain, Straumann® PrefGel and Straumann® BoneCeramic were not needed in order to resolve the FDA issues.
Straumann has changed the delivery mechanism of Straumann® PrefGel from a pipette to a syringe, which will help to ensure easier, more effective handling of the root conditioner.

This entry was posted in Dental Implant Industry. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>